Short answer

Assembly Biosciences Inc (ASMB) filed its fiscal 2015 10-K annual report with the SEC on Mar 11, 2016.

Top risk flagged: FDA approval risk: Both HBV and microbiome candidates remained in late preclinical development, with no approved products or product revenue

Assembly Biosciences Inc FY2015 10-K analysis

AI summary of each section, grounded in the filing text

Oral HBV-cure and microbiome therapeutics platforms targeting hard-to-treat infectious diseases
2015 emphasis on AB-M101, a synthetic microbiome therapy for C. difficile infections, and GEMICEL targeted lower-GI delivery
Gemicel scintigraphy study demonstrated bolus release in the ileum and ascending colon in healthy volunteers
R&D expense $15.1M, including $10.81M for HBV and $4.30M for Microbiome programs
Clinical transition planned: first HBV CpAM and AB-M101 Phase Ib trials targeted for the second half of 2016

Revenue $0, no approved products; accumulated deficit $163.97 million at December 31, 2015
Net loss $28.5 million vs $23.8 million; R&D expense $18.36 million, up 71.3% from $10.72 million
Best-performing program HBV R&D $10.81 million, up from $2.54 million; Microbiome $4.30 million vs $1.56 million
Operating cash flow $(18.7) million; investing $(64.9) million, including $69.8 million securities purchases; financing $81.6 million
Outlook: clinical trials anticipated in second half of 2016; additional funding needed, with financing availability a key risk

FDA approval risk: Both HBV and microbiome candidates remained in late preclinical development, with no approved products or product revenue
Financing risk: Cash resources expected to fund operations only into fourth quarter 2017, with additional capital required thereafter
Manufacturing vulnerability: No internal manufacturing facilities, requiring third-party contractors for clinical and commercial supply
Competitive disruption: Larger pharmaceutical companies developing competing HBV and CDI treatments could render candidates noncompetitive
Key-person dependency: Loss of HBV founder Adam Zlotnick could materially impair program development after his consulting term expires July 11, 2017

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.